Evidence mapPaperPMID 35405973Full record

Trial reportNutrients2022

Effects of Vitamin D Supplementation on 24-Hour Blood Pressure in Patients with Low 25-Hydroxyvitamin D Levels: A Randomized Controlled Trial.

Verena Theiler-Schwetz, Christian Trummer, Martin R Grübler, Martin H Keppel, Armin Zittermann, Andreas Tomaschitz, Spyridon N Karras, Winfried März, Stefan Pilz, Stephanie Gängler

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Latest Knowledge on the Role of Vitamin D in Hypertension.International journal of molecular sciences · 2023
    Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Verena Theiler-SchwetzDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Christian TrummerDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Martin R GrüblerDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-1761-2914
Martin H KeppelDepartment of Laboratory Medicine, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.ORCID 0000-0003-3448-3349
Armin ZittermannClinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen (NRW), Ruhr University Bochum, 32545 Bad Oeynhausen, Germany.ORCID 0000-0001-6085-6554
Andreas TomaschitzHealth Center Trofaiach-Gössgrabenstrasse, 8793 Trofaiach, Austria.ORCID 0000-0001-6315-3934
Spyridon N KarrasNational Scholarship Foundation, 55535 Thessaloniki, Greece.ORCID 0000-0002-4225-2746
Winfried MärzClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria.
Stefan PilzDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Stephanie GänglerCenter on Aging and Mobility, University Hospital Zurich, City Hospital Waid&Triemli and University of Zurich, 8006 Zurich, Switzerland.
Medical University of Graz · ATFrontier Science Foundation-Hellas · GRHeart and Diabetes Center North Rhine-Westphalia · DEParacelsus Medical University · ATUniversity of Zurich · CH

Funding

National Bank of Austria 13878 and 13905
6 · The paper itself

Abstract

Accumulating evidence suggests that potential cardiovascular benefits of vitamin D supplementation may be restricted to individuals with very low 25-hydroxyvitamin D (25(OH)D) concentrations; the effect of vitamin D on blood pressure (BP) remains unclear. We addressed this issue in a post hoc analysis of the double-blind, randomized, placebo-controlled Styrian Vitamin D Hypertension Trial (2011−2014) with 200 hypertensive patients with 25(OH)D levels <30 ng/mL. We evaluated whether 2800 IU of vitamin D3/day or placebo (1:1) for 8 weeks affects 24-hour systolic ambulatory BP in patients with 25(OH)D concentrations <20 ng/mL, <16 ng/mL, and <12 ng/mL and whether achieved 25(OH)D concentrations were associated with BP measures. Taking into account correction for multiple testing, p values < 0.0026 were considered significant. No significant treatment effects on 24-hour BP were observed when different baseline 25(OH)D thresholds were used (all p-values > 0.30). However, there was a marginally significant trend towards an inverse association between the achieved 25(OH)D level with 24-hour systolic BP (−0.196 per ng/mL 25(OH)D, 95% CI (−0.325 to −0.067); p = 0.003). In conclusion, we could not document the antihypertensive effects of vitamin D in vitamin D-deficient individuals, but the association between achieved 25(OH)D concentrations and BP warrants further investigations on cardiovascular benefits of vitamin D in severe vitamin D deficiency.

Indexed as

HypertensionVitamin D DeficiencyBlood PressureCalcifediolCholecalciferolDietary SupplementsDouble-Blind MethodHumansVitamin DVitamins25-hydroxyvitamin DCalcifediolCholecalciferolVitamin DVitaminsblood pressurecardiovascular riskcholecalciferolvitamin D deficiency

Identifiers

PMID35405973
PMCPMC9003372
OpenAlexW4221133635

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.